Parkinson's Disease Therapeutic Market Expands with Rising Prevalence and AI-Enabled Drug Discovery

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Parkinson's Disease Therapeutic Market - (By Drugs (Carbidopa-levodopa, Dopamine agonists, Mao-b inhibitors, COMT inhibitors, Anticholinergics, Others), By Distribution Channel (Hospital pharmacy, Retail pharmacy, Online pharmacy), By Brand (Branded, Generics), By Route of Administration (Oral, Injectable, Intestinal Infusion, Subcutaneous, Others)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031."

According to the latest research by InsightAce Analytic, the Global Parkinson's Disease Therapeutic Market is valued at US$ 4.22 Bn in 2023, and it is expected to reach US$ 6.51 Bn by 2031, with a CAGR of 5.7% during the forecast period of 2024-2031.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2587

Parkinson's disease (PD) is a progressive neurodegenerative disorder primarily characterized by motor impairments, with existing therapeutic approaches largely focused on alleviating symptoms and improving patients' quality of life.

The Parkinson's disease therapeutics market is witnessing steady expansion, driven by growing awareness and advancements in early disease detection. Innovations in diagnostic techniques-such as advanced neuroimaging tools and the identification of specific biomarkers-are enabling earlier and more accurate diagnoses, which in turn enhance treatment outcomes and therapeutic precision. Moreover, increasing investments in research and development from both pharmaceutical companies and public health organizations are fostering significant innovation in drug discovery and disease management.

Strategic alliances between biotechnology enterprises and academic institutions are further expediting the development of novel and disease-modifying therapies. Additionally, the integration of digital health technologies, including wearable monitoring systems and telemedicine platforms, is transforming disease monitoring and treatment adherence. These advancements collectively contribute to improved patient outcomes and are expected to sustain long-term growth within the Parkinson's disease therapeutics market

List of Prominent Players in the Parkinson's Disease Therapeutic Market:
• Teva Pharmaceutical Industries Ltd.,
• Novartis AG
• GlaxoSmithKline Plc.
• AbbVie Inc.
• Merck & Co. Inc.,
• Zydus Cadila
• Dr. Reddy's
• Sun Pharmaceutical Industries Ltd.
• Cipla Inc.
• Boehringer Ingelheim International GmbH
• Denali Therapeutics Inc.
• Biogen Inc.
• Prevail Therapeutics
• Eli Lilly and Company
• Voyager Therapeutics.
• Intas Pharmaceuticals Ltd.
• Torrent Pharmaceuticals Ltd.
• Amneal Pharmaceuticals
• Aurobindo Pharma Limited
• Accord Healthcare Ltd.

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-02

Market Dynamics
Drivers:
The growth of the Parkinson's disease therapeutics market is primarily driven by the increasing global prevalence of the disorder, particularly among aging populations. Rising awareness and advancements in diagnostic technologies are enabling earlier and more accurate detection of Parkinson's disease, thereby heightening the demand for effective and targeted treatment solutions. The market is also benefiting from the diversification of therapeutic options designed to address various disease stages and symptom severities, contributing to improved clinical outcomes.

Furthermore, the integration of artificial intelligence (AI) and machine learning in drug discovery and development is transforming the research landscape. These technologies facilitate the rapid analysis of complex biological data, enhance predictive modeling for clinical trials, and optimize regulatory processes-collectively accelerating the development and approval of novel therapies while reducing costs. Such technological advancements are expected to play a pivotal role in sustaining market growth over the coming years.

Challenges:
Despite notable progress, the Parkinson's disease therapeutics market faces several challenges, including a decline in the approval rate of new drugs. This slowdown restricts the introduction of innovative treatment options, thereby limiting therapeutic diversity and patient choice. The constrained pipeline of novel drugs may also hinder advancements in disease management and reduce competition, which can lead to higher costs for existing therapies. These factors collectively impede the pace of innovation and present a significant barrier to addressing the evolving clinical demands of Parkinson's disease patients.

Regional Trends:
North America continues to dominate the global Parkinson's disease therapeutics market, driven by a high prevalence of the disease among its aging population and strong investments in neurological research. The region also benefits from advanced healthcare infrastructure and early adoption of innovative therapeutic technologies. Europe holds a substantial market share as well, supported by comprehensive healthcare systems, robust regulatory frameworks, and increasing collaboration between academic institutions and pharmaceutical companies. The presence of key industry players, coupled with expanding strategic partnerships, is further enhancing global research and development capabilities, reinforcing the market's overall growth trajectory.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2587

Recent Developments:
• In March 2024, Sanofi and Cipla have formed an exclusive collaboration to distribute and promote Sanofi India's Central Nervous System (CNS) product range in India. Under this collaboration, Cipla will assume the responsibility of distributing Sanofi India's six CNS brands, which includes Frisium®, a prominent brand in the anti-epileptic drug field.
• In Oct 2022, Biogen and Denali Therapeutics commenced the Phase 3 LIGHTHOUSE Study in Parkinson's Disease linked to LRRK2 Pathogenic Mutations. The main objective of the LIGHTHOUSE trial was to measure the duration until proven deterioration, evaluated using the Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS), during the treatment term of up to 180 weeks.

Segmentation of Parkinson's Disease Therapeutic Market-
By Drugs
• Carbidopa-levodopa
• Dopamine agonists
• Mao-b inhibitors
• COMT inhibitors
• Anticholinergics
• Others
By Distribution Channel-
• Hospital pharmacy
• Retail pharmacy
• Online pharmacy
By Brand
• Branded
• Generics
By Route of Administration
• Oral,
• Injectable,
• Intestinal Infusion,
• Subcutaneous
• Others
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of Middle East and Africa

Read Overview Report- https://www.insightaceanalytic.com/report/parkinsons-disease-therapeutic-market/2587

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: https://www.insightaceanalytic.com/
Tel : +1 607 400-7072
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.